+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Diabetes Care Devices Market - Growth, Trends, and Forecast (2020 - 2025)

  • ID: 5174954
  • Report
  • August 2020
  • Region: Global
  • 150 pages
  • Mordor Intelligence
UP TO OFF
until Dec 31st 2020

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Abbott
  • Ascensia Diabetes Care
  • Dexcom
  • Johnson & Johnson
  • Medtronic
  • Omnipod
  • MORE
The diabetes care devices market is expected to register a CAGR greater than 6.8% during the forecast period (2020-2025). North America is anticipated to dominate the market during the forecast period, owing to the rising prevalence of obesity in the region. There has been a significant rise in insulin delivery systems technology, ranging from insulin injections to insulin pumps. Technological innovations and advancements offer many conveniences in measuring blood glucose levels. One such advancement in monitoring the blood glucose levels is the continuous glucose monitoring devices.

Key Market Trends

Rising Prevalence of Diabetes

The diabetes care devices market reached USD 69.7 billion in 2019, and it is anticipated to register a CAGR of 4.6% during the forecast period (2020-2025). Approximately 4.2 million adults aged 20-79 years were estimated to die as a result of diabetes and its complications in 2019. This is equivalent to one death every eight seconds. Diabetes is estimated to be associated with 11.3% of global deaths from all causes among people in this age group. Almost half (46.2%) of the deaths associated with diabetes among the age group of 20-79 years are of people under the age of 60 years, i.e., the working-age group. Globally, there are more deaths associated with diabetes in women (2.3 million) than in men (1.9 million).

North America to Dominate the Monitoring Devices Segment

The factors attributing to the North American market growth is the rising prevalence of diabetes, caused mainly due to urbanization and sedentary lifestyles. Asia-Pacific is anticipated to grow tremendously during the forecast period, owing to factors, such as a high prevalence of diabetes, a growing obese population, and government initiatives of raising awareness regarding diabetic care. According to IDF, in 2019, USD 324.5 billion was spent on diabetes in the region, which is 42.7% of the total global health expenditure on diabetes. In North America, USD 294.6 billion was spent in the United States alone. The mean annual expenditure per person with diabetes was highest in the United States (USD 9,506), followed by Canada (USD 4,397).

Competitive Landscape

There have been constant innovations driven by manufacturers to compete and struggle in the market. The major players, such as Abbott and Medtronic, resort to inorganic market strategies, such as mergers and acquisitions, to establish market dominance, while also adhering to organic growth strategies, which is evident from the R&D spending of these companies. Examples of a few strategic outcomes include:

In March 2018, Medtronic PLC received the US Food and Drug Administration (FDA) approval for its Guardian (TM) Connect Continuous Glucose Monitoring (CGM) system, for people with diabetes aged between 14 and 75 years.
  • In October 2019, the US Food and Drug Administration (FDA) cleared the Dexcom G6 Pro Continuous Glucose Monitoring (CGM) System for healthcare professionals to use on patients aged between two years and above.
Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott
  • Ascensia Diabetes Care
  • Dexcom
  • Johnson & Johnson
  • Medtronic
  • Omnipod
  • MORE
1 INTRODUCTION
1.1 Study Assumptions
1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.3 Market Restraints
4.4 Porter's Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry

5 Market Segmentation
5.1 Monitoring Devices (Value and Volume, 2012-2025)
5.1.1 Self-monitoring Blood Glucose Devices
5.1.1.1 Glucometer Devices
5.1.1.2 Test Strips
5.1.1.3 Lancets
5.1.2 Continuous Glucose Monitoring
5.1.2.1 Sensors
5.1.2.2 Durables
5.2 Management Devices (Value and Volume, 2012-2025)
5.2.1 Insulin Pumps
5.2.1.1 Insulin Pump Device
5.2.1.2 Insulin Pump Reservoir
5.2.1.3 Infusion Set
5.2.2 Insulin Syringes
5.2.3 Insulin Cartridges
5.2.4 Disposable Pens
5.2.5 Jet Injectors
5.3 Geography
5.3.1 North America
5.3.1.1 United States (Value and Volume, 2012 - 2025)
5.3.1.1.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.1.1.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
5.3.1.2 Canada (Value and Volume, 2012 - 2025)
5.3.1.2.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.1.2.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
5.3.1.3 Rest of North America (Value and Volume, 2012 - 2025)
5.3.1.3.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.1.3.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
5.3.2 Europe
5.3.2.1 France (Value and Volume, 2012 - 2025)
5.3.2.1.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.2.1.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
5.3.2.2 Germany (Value and Volume, 2012 - 2025)
5.3.2.2.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.2.2.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
5.3.2.3 Italy (Value and Volume, 2012 - 2025)
5.3.2.3.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.2.3.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
5.3.2.4 Spain (Value and Volume, 2012 - 2025)
5.3.2.4.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.2.4.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
5.3.2.5 United Kingdom (Value and Volume, 2012 - 2025)
5.3.2.5.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.2.5.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
5.3.2.6 Russia (Value and Volume, 2012 - 2025)
5.3.2.6.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.2.6.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
5.3.2.7 Rest of Europe (Value and Volume, 2012 - 2025)
5.3.2.7.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.2.7.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
5.3.3 Latin America
5.3.3.1 Mexico (Value and Volume, 2012 - 2025)
5.3.3.1.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.3.1.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
5.3.3.2 Brazil (Value and Volume, 2012 - 2025)
5.3.3.2.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.3.2.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
5.3.3.3 Rest of Latin America (Value and Volume, 2012 - 2025)
5.3.3.3.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.3.3.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
5.3.4 Asia-Pacific
5.3.4.1 Japan (Value and Volume, 2012 - 2025)
5.3.4.1.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.4.1.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
5.3.4.2 South Korea (Value and Volume, 2012 - 2025)
5.3.4.2.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.4.2.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
5.3.4.3 China (Value and Volume, 2012 - 2025)
5.3.4.3.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.4.3.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
5.3.4.4 India (Value and Volume, 2012 - 2025)
5.3.4.4.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.4.4.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
5.3.4.5 Australia (Value and Volume, 2012 - 2025)
5.3.4.5.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.4.5.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
5.3.4.6 Vietnam (Value and Volume, 2012 - 2025)
5.3.4.6.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.4.6.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
5.3.4.7 Malaysia (Value and Volume, 2012 - 2025)
5.3.4.7.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.4.7.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
5.3.4.8 Indonesia (Value and Volume, 2012 - 2025)
5.3.4.8.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.4.8.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
5.3.4.9 Philippines (Value and Volume, 2012 - 2025)
5.3.4.9.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.4.9.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
5.3.4.10 Thailand (Value and Volume, 2012 - 2025)
5.3.4.10.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.4.10.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
5.3.4.11 Rest of Asia-Pacific (Value and Volume, 2012 - 2025)
5.3.4.11.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.4.11.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
5.3.5 Middle-East and Africa
5.3.5.1 Saudi Arabia (Value and Volume, 2012 - 2025)
5.3.5.1.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.5.1.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
5.3.5.2 Iran (Value and Volume, 2012 - 2025)
5.3.5.2.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.5.2.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
5.3.5.3 Egypt (Value and Volume, 2012 - 2025)
5.3.5.3.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.5.3.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
5.3.5.4 Oman (Value and Volume, 2012 - 2025)
5.3.5.4.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.5.4.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
5.3.5.5 South Africa (Value and Volume, 2012 - 2025)
5.3.5.5.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.5.5.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)
5.3.5.6 Rest of Middle-East and Africa (Value and Volume, 2012 - 2025)
5.3.5.6.1 By Monitoring Device (Self-monitoring Blood Glucose, Continuous Glucose Monitoring)
5.3.5.6.2 By Management Device (Insulin Pumps, Insulin Syringes, Insulin Cartridges, Disposable Pens, and Jet Injectors)

6 MARKET INDICATORS
6.1 Type-1 Diabetes Population (2012-2025)
6.2 Type-2 Diabetes Population (2012-2025)

7 COMPETITIVE LANDSCAPE
7.1 Company Profiles
7.1.1 Abbott
7.1.2 F. Hoffmann-La Roche AG
7.1.3 Johnson & Johnson
7.1.4 Dexcom
7.1.5 Medtronic
7.1.6 Novo Nordisk
7.1.7 Ascensia Diabetes Care
7.1.8 AgaMatrix
7.1.9 Bionime Corporation
7.1.10 Omnipod
7.1.11 Medisana
7.1.12 Trivida
7.1.13 Rossmax International Ltd

8 MARKET OPPORTUNITIES AND FUTURE TRENDS
Note: Product cover images may vary from those shown

Loading
LOADING...

  • Abbott
  • F. Hoffmann-La Roche AG
  • Johnson & Johnson
  • Dexcom
  • Medtronic
  • Novo Nordisk
  • Ascensia Diabetes Care
  • AgaMatrix
  • Bionime Corporation
  • Omnipod
  • Medisana
  • Trivida
  • Rossmax International Ltd
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll